Braess, Jan
,
Amler, Susanne
Kreuzer, Karl-Anton
Spiekermann, Karsten
Lindemann, Hans Walter
Lengfelder, Eva
Graeven, Ullrich
Staib, Peter
Ludwig, Wolf-Dieter
Biersack, Harald
Ko, Yon-Dschun
Uppenkamp, Michael J.
De Wit, Maike
Korsten, Stefan
Peceny, Rudolf
Gaska, Tobias
Schiel, Xaver
Behringer, Dirk M.
Kiehl, Michael G.
Zinngrebe, Bettina
Meckenstock, Gerald
Roemer, Eva
Medgenberg, Dirk
Spaeth-Schwalbe, Ernst
Massenkeil, Gero
Hindahl, Heidrun
Schwerdtfeger, Rainer
Trenn, Guido
Sauerland, Cristina
Koch, Raphael
Lablans, Martin
Faldum, Andreas
Görlich, Dennis
Bohlander, Stefan K.
Schneider, Stephanie
Dufour, Annika
Buske, Christian
Fiegl, Michael
Subklewe, Marion
Braess, Birgit
Unterhalt, Michael
Baumgartner, Anja
Wörmann, Bernhard
Beelen, Dietrich
Hiddemann, Wolfgang
Article History
Received: 16 May 2018
Revised: 26 July 2018
Accepted: 9 August 2018
First Online: 1 October 2018
Compliance with ethical standards
:
: Jan Braess has received research funding from Amgen and Janssen. Eva Elisabeth Lengfelder has received travel & accommodation expenses from Teva and Novartis. Ullrich Graeven has received honoraria from Amgen, Roche, Bayer, Sanofi, AbbVie, Servier, and Boehringer; has a consulting or advisory role in Baxalta, Servier, Roche, and Novartis; and has received travel & accommodation expenses from Merck and Sanofi. Dirk Behringer has a consulting or advisory role in Roche and BMS. Gero Massenkeil has received honoraria from Sanofi; has a consulting or advisory role in Sanofi; and is in speakers’ bureau in Sanofi. Stefan Bohlander has received honoraria from Roche. Wolfgang Hiddemann has received honoraria from Roche, Gilead, and Janssen; is in speakers’ bureau in Roche, Gilead, and Janssen; has received research funding from Amgen, Roche, Gilead, and Janssen; has received travel & accommodation expenses from Amgen, Roche, Gilead, and Janssen. All other authors declare that they have no conflict of interest.